Clinical Trial Update: Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing apatinib plus capecitabine versus capecitabine alone as maintenance therapy in advanced triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Apatinib (apatinib)
• Capecitabine (capecitabine)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Triple-negative Breast Cancer | Phase 2 | Status: UNKNOWN